Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
186 results about "SGLT2 Inhibitor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Any inhibitor of the sodium-glucose co-transporter subtype 2 (SGLT2) with antihyperglycemic activity. By binding to and blocking SGLT2, these inhibitors suppress reabsorption of glucose in the proximal tubule within the kidneys and thereby enhancing urinary excretion of glucose. This eventually normalizes blood glucose levels. SGLT2, a transport system exclusively expressed in the proximal renal tubules, mediates about 90% of renal glucose reabsorption from tubular fluid.
C-aryl glucoside SGLT2 inhibitors and method
Owner:BRISTOL MYERS SQUIBB CO
C-aryl glucoside SGLT2 inhibitors and method
Owner:ASTRAZENECA AB
Pharmaceutical composition comprising a sglt2 inhibitor in combination with a dpp-iv inhibitor
InactiveUS20110098240A1Good effectBiocideSenses disorderIGT - Impaired glucose toleranceAcute hyperglycaemia
The invention relates to a pharmaceutical composition according to claim 1 comprising a SGLT2 inhibitor in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
Owner:BOEHRINGER INGELHEIM INT GMBH
Pharmaceutical composition, methods for treating and uses thereof
InactiveUS20110046076A1Improve blood sugar controlPrevent and slow progressionBiocideMetabolism disorderAcute hyperglycaemiaIGT - Impaired glucose tolerance
The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
Owner:BOEHRINGER INGELHEIM INT GMBH
C-aryl glucoside SGLT2 inhibitors and method
Owner:BRISTOL MYERS SQUIBB CO
Methods for Treating Obesity Employing an SGLT2 Inhibitor and Compositions Thereof
ActiveUS20080234367A1Promoting and increasing and enhancing glucosuriaBiocideMetabolism disorderSGLT2 InhibitorAnti-Obesity Agents
Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which comprises an SGLT2 inhibitor, alone or in combination with another anti-obesity agent, and a pharmaceutically acceptable carrier thereof.
Owner:ASTRAZENECA AB
C-aryl glucoside SGLT2 inhibitor
InactiveCN101503399AGood treatment effectOrganic active ingredientsOrganic chemistryDiseaseDiabetes mellitus
The invention relates to a C-aryl glucoside derivative indicated by a general formula I, as well as a usage and a composition thereof. The C-aryl glucoside derivative has a good effect in inhibiting SGLT. The composition can be separately used or used together with other antidiabetic medicine or other therapeutic agent and can be used for preventing or curing diabetes and other relevant diseases.
Owner:马萨诸塞州白鹭有限责任公司
C-aryl glucoside SGLT2 inhibitors and method
Owner:ASTRAZENECA AB
Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
ActiveUS8080580B2Lower blood sugar levelsImpaired glucose toleranceBiocideSenses disorderDiseaseSGLT2 Inhibitor
Compounds of Formula (I) are described herein and the uses thereof for the treatment of diseases, conditions and / or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).
![Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/90a40ec1-a353-4bb5-951d-923da8e44698/US08080580-20111220-D00001.png "Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives")
![Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/90a40ec1-a353-4bb5-951d-923da8e44698/US08080580-20111220-D00002.png "Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives")
![Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/90a40ec1-a353-4bb5-951d-923da8e44698/US08080580-20111220-D00003.png "Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives")
Owner:PFIZER INC
Pharmaceutical composition, methods for treating and uses thereof
InactiveUS20130035281A1Good effectFew adverse effectAntibacterial agentsSenses disorderIGT - Impaired glucose toleranceAcute hyperglycaemia
The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and a GLP-1 receptor agonist which is suitable in the treatment or prevention of diabetes mellitus, impaired glucose tolerance, hyperglycemia or other conditions. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
Owner:BOEHRINGER INGELHEIM INT GMBH
Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof
ActiveCN102757415AExtended half-lifePromote absorptionSenses disorderSaccharide with carbocyclic radicalsDiseaseSodium dependent
A compound represented by formula I, or a pharmaceutically acceptable salt, solvate, polymorph, enantiomer or racemic mixture thereof, wherein, R1 and R2 are independently hydrogen, -OH, alkyl, -CF3, -OCHF2, -OCF3 or halogen,R3 is cycloalkyl, -OCH2CF3, -OCH2CHF2, -OCH2CH2F or -OCH2CH3,R4 is hydrogen, -OH, -O aryl, -OCH2 aryl, alkyl, cycloalkyl, -CF3, -OCHF2, -OCF3, -OCH2CF3, -OCH2CHF2, -OCH2CH2F or halogen,A is -CX1X2, wherein X1 and X2 are independently H, F and Cl, and when both X1 and X2 are H, R3 is other than -OCH2CH3. The compound has an activity of inhibitors of sodium-dependent glucose transport protein. A method for preparing the compound. A pharmaceutical composition comprising the compound. A use of the compound and pharmaceutical composition thereof in the preparation of medicaments of SGLT2 inhibitors for treating a disease of interest.
Owner:BEIJING PRELUDE PHARM SCI & TECH
Methods of treatment, pharmaceutical compositions and uses thereof
InactiveUS20130137646A1Increase body weightReduce weightBiocideNervous disorderSGLT2 InhibitorNeuroleptic agents
Owner:BOEHRINGER INGELHEIM INT GMBH
Pharmaceutical composition comprising a sglt2 inhibitor in combination with a dpp-iv inhibitor
InactiveUS20130096076A1Good effectBiocideSenses disorderIGT - Impaired glucose toleranceAcute hyperglycaemia
Owner:BOEHRINGER INGELHEIM INT GMBH
Thiazole derivatives as SGLT2 inhibitors and pharmaceutical composition comprising same
ActiveUS8586550B2Prevention and/or treatment of metabolic disordersReduce usageBiocideSaccharide with heterocyclic radicalsSodium dependentSGLT2 Inhibitor
The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.
Owner:THE GREEN CROSS CORP
Treatment of metabolic disorders in equine animals
The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and / or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates to one or more SGLT2 inhibitors or a pharmaceutically acceptable form thereof for use in the treatment and / or prevention of laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and / or Equine Metabolic Syndrome in an equine animal.
Owner:BOEHRINGER LNGELHEIM VETMEDICA GMBH
Five-membered heteroaromatics tolylene glucoside and preparation method and use thereof
The invention relates to the field of diabetes-related drugs, in particular to an SGLT2 inhibitor containing the structure of five-membered heteroaromatics tolylene glucoside and the preparation method thereof and application thereof for preparing the drugs of diabetes, wherein, the group is defined in the specification.
Owner:TIANJIN INSTITUTE OF PHARMA RESEARCH
Pharmaceutical composition, methods for treating and uses thereof
InactiveUS20120283169A1Preventing and slowing progression of and delaying and treating diabetesGood effectOrganic active ingredientsSenses disorderAcute hyperglycaemiaIGT - Impaired glucose tolerance
The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions
Owner:BOEHRINGER INGELHEIM INT GMBH
Pharmaceutical composition, methods for treating and uses thereof
ActiveUS20140038911A1Good effectFew complianceBiocideMetabolism disorderAcute hyperglycaemiaIGT - Impaired glucose tolerance
Owner:BOEHRINGER INGELHEIM INT GMBH
Pharmaceutical composition, methods for treating and uses thereof
InactiveUS20140087996A1Good effectFew adverse effectAntibacterial agentsSenses disorderIGT - Impaired glucose toleranceAcute hyperglycaemia
The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and a GLP-1 receptor agonist which is suitable in the treatment or prevention of diabetes mellitus, impaired glucose tolerance, hyperglycemia or other conditions. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
Owner:BOEHRINGER INGELHEIM INT GMBH
Processes for the preparation of SGLT2 inhibitors
ActiveUS8283454B2Organic active ingredientsSaccharide with carbocyclic radicalsSodium dependentSGLT2 Inhibitor
Provided are processes for the preparation of complexes that are useful in purifying compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The processes can reduce the number of steps needed to obtain the target compounds and the complexes formed in the processes are typically provided in a crystalline form.
Owner:THERACOSBIO LLC
Treatment of metabolic disorders in equine animals
The present invention relates to SGLT2 inhibitor or a pharmaceutically acceptable form thereof for use in the treatment and / or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates the SGLT2 inhibitor or a pharmaceutically acceptable form thereof for use in the treatment and / or prevention of insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, and / or regional adiposity in an equine animal.
Owner:BOEHRINGER LNGELHEIM VETMEDICA GMBH
Treatment of metabolic disorders in feline animals
ActiveUS20150164856A1Reduce doseReduce frequencyBiocideNervous disorderAcute hyperglycaemiaDyslipidemia
The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and / or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and / or Syndrome X (metabolic syndrome) and / or loss of pancreatic beta cell function and / or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and / or maintained.
Owner:BOEHRINGER LNGELHEIM VETMEDICA GMBH
Bilayer tablet formulations
The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.
Owner:ASTRAZENECA AB
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
InactiveUS20140088027A1Prevent and slow progressionImprove blood sugar controlBiocideNervous disorderAcute hyperglycaemiaIGT - Impaired glucose tolerance
The invention relates to a pharmaceutical composition comprising an SGLT2 inhibitor and a PPARγ agonist which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
Owner:BOEHRINGER INGELHEIM INT GMBH
Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same
ActiveUS20130090298A1Reduce usageUseful in treatmentBiocideSaccharide with heterocyclic radicalsIntestinal structureBULK ACTIVE INGREDIENT
The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.
Owner:THE GREEN CROSS CORP
Pharmaceutical composition, methods for treating and uses thereof
InactiveUS20140256624A1Good effectFew adverse effectOrganic active ingredientsSenses disorderAcute hyperglycaemiaIGT - Impaired glucose tolerance
The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions
Owner:BOEHRINGER INGELHEIM INT GMBH
Processes for the preparation of sglt2 inhibitors
ActiveUS20100222599A1Organic active ingredientsSaccharide with carbocyclic radicalsSodium dependentSGLT2 Inhibitor
Provided are processes for the preparation of complexes that are useful in purifying compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The processes can reduce the number of steps needed to obtain the target compounds and the complexes formed in the processes are typically provided in a crystalline form.
Owner:THERACOSBIO LLC
C-aryl glucoside sglt2 inhibitors and method
Owner:ASTRAZENECA AB
Methods of producing C-aryl glucoside SGLT2 inhibitors
Method for the production of C-aryl glucoside SGLT2 inhibitors useful for the treatment of diabetes and related diseases. and intermediates thereof. The C-aryl glucosides may be complexed with amino acid complex forming reagents.
Owner:BRISTOL MYERS SQUIBB CO
New C-aryl glycosidase SGLT2 (sodium glucose transporter type-2) inhibitor
ActiveCN104327027AEasy dischargeSGLT2 inhibitory activity is goodOrganic active ingredientsOrganic chemistryArylSGLT2 Inhibitor
The invention discloses a new C-aryl glycosidase SGLT2 (sodium glucose transporter type-2) inhibitor, relates to the field of medicines associated with diabetes, and in particular relates to a new C-aryl glycosidase derivative shown as the general formula (I), a preparation method thereof, compositions thereof, and use thereof in preparing hypoglycemic drugs. The C-aryl glucoside derivative has excellent effect of promoting urine discharge and in-vivo hypoglycemic activity, and compounds with equal or better in-vivo hypoglycemic activity than that of dapagliflozin are screened out, and can be used for the prevention or treatment of diabetes.
Owner:CHINA PHARM UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com